心功能障碍休克儿童的处理:儿童重症监护病房的描述性研究

IF 2.2 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Simon Anquetil , Marion Delaye , Matthieu Devred , David Brossier
{"title":"心功能障碍休克儿童的处理:儿童重症监护病房的描述性研究","authors":"Simon Anquetil ,&nbsp;Marion Delaye ,&nbsp;Matthieu Devred ,&nbsp;David Brossier","doi":"10.1016/j.acvd.2025.06.028","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>This study analyzes the management of pediatric cardiogenic shock following the recommendations of Brissaud et al. (2016), focusing on epidemiology, clinical practices, mortality rates, and associated risk factors.</div></div><div><h3>Objective</h3><div>The primary objective of this study was to describe the epidemiology and management practices of patients admitted to pediatric intensive care for cardiogenic or septic shock with cardiac dysfunction. The secondary objective was to assess the mortality rate and identify risk factors associated with mortality.</div></div><div><h3>Methods</h3><div>This multicenter retrospective study, based on CRH data, includes children (&gt;<!--> <!-->5 days and &lt;<!--> <!-->18 years old) with septic or cardiogenic shock associated with cardiac dysfunction. Epidemiological, clinical, therapeutic, and biological data, along with results from complementary investigations, were collected. Patients were classified into two groups: “deceased” and “survivors”.</div></div><div><h3>Expected results</h3><div>Among the 249 children included, the overall mortality rate was 24.9%. The leading cause of cardiac dysfunction was sepsis, with no statistically significant difference between the two groups (<em>p</em> <!-->=<!--> <!-->0.145). The primary cause of cardiogenic shock was post-cardiac arrest myocardial dysfunction (24.8%), across all etiologies. Dobutamine was the first-line inotropic agent (62.6%) (<span><span>Figure 1</span></span>), with no significant difference between groups. Milrinone use was more frequent among survivors (<em>p</em> <!-->=<!--> <!-->0.036), whereas adrenaline was more commonly administered in the deceased group (<em>p</em> <!-->&lt;<!--> <!-->0.001). Invasive ventilation was more prevalent in the deceased group (<em>p</em> <!-->&lt;<!--> <!-->0.001), whereas non-invasive ventilation was more frequent among survivors (<em>p</em> <!-->=<!--> <!-->0.002). Mortality was associated with a higher PIM3 score, invasive ventilation, neurological distress, adrenaline administration, and renal replacement therapy. A protective trend for milrinone was observed, although not statistically significant.</div></div><div><h3>Perspectives</h3><div>Management primarily relies on mechanical ventilation and first-line dobutamine administration. This interim analysis highlighted limitations in data collection methods, necessitating adjustments for the next phase of the study, which aims to compare milrinone and dobutamine.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 8","pages":"Page S262"},"PeriodicalIF":2.2000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Management of Children in Shock with Cardiac Dysfunction: A Descriptive Study in the Pediatric Intensive Care Unit\",\"authors\":\"Simon Anquetil ,&nbsp;Marion Delaye ,&nbsp;Matthieu Devred ,&nbsp;David Brossier\",\"doi\":\"10.1016/j.acvd.2025.06.028\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>This study analyzes the management of pediatric cardiogenic shock following the recommendations of Brissaud et al. (2016), focusing on epidemiology, clinical practices, mortality rates, and associated risk factors.</div></div><div><h3>Objective</h3><div>The primary objective of this study was to describe the epidemiology and management practices of patients admitted to pediatric intensive care for cardiogenic or septic shock with cardiac dysfunction. The secondary objective was to assess the mortality rate and identify risk factors associated with mortality.</div></div><div><h3>Methods</h3><div>This multicenter retrospective study, based on CRH data, includes children (&gt;<!--> <!-->5 days and &lt;<!--> <!-->18 years old) with septic or cardiogenic shock associated with cardiac dysfunction. Epidemiological, clinical, therapeutic, and biological data, along with results from complementary investigations, were collected. Patients were classified into two groups: “deceased” and “survivors”.</div></div><div><h3>Expected results</h3><div>Among the 249 children included, the overall mortality rate was 24.9%. The leading cause of cardiac dysfunction was sepsis, with no statistically significant difference between the two groups (<em>p</em> <!-->=<!--> <!-->0.145). The primary cause of cardiogenic shock was post-cardiac arrest myocardial dysfunction (24.8%), across all etiologies. Dobutamine was the first-line inotropic agent (62.6%) (<span><span>Figure 1</span></span>), with no significant difference between groups. Milrinone use was more frequent among survivors (<em>p</em> <!-->=<!--> <!-->0.036), whereas adrenaline was more commonly administered in the deceased group (<em>p</em> <!-->&lt;<!--> <!-->0.001). Invasive ventilation was more prevalent in the deceased group (<em>p</em> <!-->&lt;<!--> <!-->0.001), whereas non-invasive ventilation was more frequent among survivors (<em>p</em> <!-->=<!--> <!-->0.002). Mortality was associated with a higher PIM3 score, invasive ventilation, neurological distress, adrenaline administration, and renal replacement therapy. A protective trend for milrinone was observed, although not statistically significant.</div></div><div><h3>Perspectives</h3><div>Management primarily relies on mechanical ventilation and first-line dobutamine administration. This interim analysis highlighted limitations in data collection methods, necessitating adjustments for the next phase of the study, which aims to compare milrinone and dobutamine.</div></div>\",\"PeriodicalId\":55472,\"journal\":{\"name\":\"Archives of Cardiovascular Diseases\",\"volume\":\"118 8\",\"pages\":\"Page S262\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Cardiovascular Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1875213625003559\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Cardiovascular Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1875213625003559","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

本研究根据Brissaud等人(2016)的建议分析了小儿心源性休克的管理,重点关注流行病学、临床实践、死亡率和相关危险因素。目的本研究的主要目的是描述心源性或感染性休克合并心功能障碍住院儿童重症监护患者的流行病学和管理实践。次要目的是评估死亡率并确定与死亡率相关的危险因素。方法基于CRH数据的多中心回顾性研究纳入了感染性休克或心源性休克合并心功能障碍的儿童(5天大,18岁)。收集了流行病学、临床、治疗和生物学数据以及补充调查的结果。病人被分为两组:“死者”和“幸存者”。预期结果在纳入的249名儿童中,总死亡率为24.9%。导致心功能障碍的主要原因是败血症,两组比较差异无统计学意义(p = 0.145)。在所有病因中,心源性休克的主要原因是心脏骤停后心肌功能障碍(24.8%)。多巴酚丁胺是一线的肌力药物(62.6%)(图1),两组间无显著差异。米力农在幸存者中使用更频繁(p = 0.036),而肾上腺素在死亡组中更常见(p < 0.001)。有创通气在死者组中更为普遍(p < 0.001),而非有创通气在幸存者中更为常见(p = 0.002)。死亡率与较高的PIM3评分、有创通气、神经窘迫、肾上腺素管理和肾脏替代治疗相关。米力农有保护作用,但没有统计学意义。治疗主要依靠机械通气和一线多巴酚丁胺治疗。这一中期分析强调了数据收集方法的局限性,需要对研究的下一阶段进行调整,该阶段旨在比较米力酮和多巴酚丁胺。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Management of Children in Shock with Cardiac Dysfunction: A Descriptive Study in the Pediatric Intensive Care Unit

Introduction

This study analyzes the management of pediatric cardiogenic shock following the recommendations of Brissaud et al. (2016), focusing on epidemiology, clinical practices, mortality rates, and associated risk factors.

Objective

The primary objective of this study was to describe the epidemiology and management practices of patients admitted to pediatric intensive care for cardiogenic or septic shock with cardiac dysfunction. The secondary objective was to assess the mortality rate and identify risk factors associated with mortality.

Methods

This multicenter retrospective study, based on CRH data, includes children (> 5 days and < 18 years old) with septic or cardiogenic shock associated with cardiac dysfunction. Epidemiological, clinical, therapeutic, and biological data, along with results from complementary investigations, were collected. Patients were classified into two groups: “deceased” and “survivors”.

Expected results

Among the 249 children included, the overall mortality rate was 24.9%. The leading cause of cardiac dysfunction was sepsis, with no statistically significant difference between the two groups (p = 0.145). The primary cause of cardiogenic shock was post-cardiac arrest myocardial dysfunction (24.8%), across all etiologies. Dobutamine was the first-line inotropic agent (62.6%) (Figure 1), with no significant difference between groups. Milrinone use was more frequent among survivors (p = 0.036), whereas adrenaline was more commonly administered in the deceased group (p < 0.001). Invasive ventilation was more prevalent in the deceased group (p < 0.001), whereas non-invasive ventilation was more frequent among survivors (p = 0.002). Mortality was associated with a higher PIM3 score, invasive ventilation, neurological distress, adrenaline administration, and renal replacement therapy. A protective trend for milrinone was observed, although not statistically significant.

Perspectives

Management primarily relies on mechanical ventilation and first-line dobutamine administration. This interim analysis highlighted limitations in data collection methods, necessitating adjustments for the next phase of the study, which aims to compare milrinone and dobutamine.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Archives of Cardiovascular Diseases
Archives of Cardiovascular Diseases 医学-心血管系统
CiteScore
4.40
自引率
6.70%
发文量
87
审稿时长
34 days
期刊介绍: The Journal publishes original peer-reviewed clinical and research articles, epidemiological studies, new methodological clinical approaches, review articles and editorials. Topics covered include coronary artery and valve diseases, interventional and pediatric cardiology, cardiovascular surgery, cardiomyopathy and heart failure, arrhythmias and stimulation, cardiovascular imaging, vascular medicine and hypertension, epidemiology and risk factors, and large multicenter studies. Archives of Cardiovascular Diseases also publishes abstracts of papers presented at the annual sessions of the Journées Européennes de la Société Française de Cardiologie and the guidelines edited by the French Society of Cardiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信